Compare Incyte Corporation (INCY) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Incyte Corporation trades at $118.08 (market cap $23.11B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.63. The key difference: Incyte Corporation is trading nearer its 52-week high, Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF nearer its low. Which is the better fit depends on your goals.
| INCY | PDBC | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | — |
52-Week High | $118.52 | $18.91 |
52-Week Low | $67.38 | $12.90 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
PDBC trades at $17.38, up 0.75% with strong institutional interest as Geneos Wealth Management increased its position by 150.6% in Q1 2026. The ETF shows bullish technical signals with moving averages supporting upward momentum, though RSI levels indicate potential overbought conditions. PDBC has delivered 37% returns since March 2024, outperforming the S&P 500 by nearly 10 percentage points, driven by commodity price strength and Middle East supply disruptions.
Outlook remains positive given commodity momentum and inflation hedging demand, but risks include recent commodity weakness and the fund's complex tax structure. The ETF's annual distribution is unpredictable, swinging with commodity prices, which may disappoint income-focused investors despite strong total returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
